International Society for CNS Clinical Trials and Methodology Conference

Clinician-administered assessments and impact on placebo response in recent major depressive disorder (MDD) clinical trials

VIEW

Medicinal & Bioorganic Chemistry Foundation (MBCF) 2025

First-in-human Translation of of a Biomimetic Glyceride Prodrug Platform: Enabling Avoidance of First-pass Metabolism via Lymphatic Absorption

VIEW

American College of Neuropsychopharmacology (ACNP) 2024

SPT-300, a First-in-Class Orally Bioavailable Prodrug of the Neurosteroid Allopregnanolone: Safety, Tolerability, and Clinical Pharmacology in Healthy Volunteers

VIEW

Society of Biological Psychiatry (SOBP) 2024

A First-in-Human Phase 1 Study of SPT-300, a First-in-Class Orally Bioavailable Prodrug of the NeurosteroidAllopregnanolone That is Absorbed via the Lymphatic System

VIEW

Society of Biological Psychiatry (SOBP) 2024

SPT-300, an Oral Prodrug of Allopregnanolone, Potently Reduces Salivary Cortisol Response to the Trier Social Stress Test in a Randomized, Placebo-Controlled Phase 2a Study in Healthy Participants

VIEW

Seaport Therapeutics
101 Seaport Blvd
Seaport Boston, MA 02210

info@seaporttx.com
Privacy Policy
Terms of Use

© 2024 Seaport Therapeutics